RDPAC药品推广行为准则 - IFPMA

主席致辞
中国政府在医疗卫生体制改
革一系列政策及最新公布的十二五
计划中明确表达了其将大大改善中
国人民福祉的宏伟规划与承诺。其
中,加强疾病预防,改善医疗卫生
服务的可及性和扩大基本医疗保险
的覆盖率等举措将对整个中国医疗
卫生体系向积极的方向发展产生根
本的影响。
与此同时,医疗卫生领域各
相关方面,包括制药行业自身,
都应当以严格遵守最高职业和伦理
道德标准的行为规范的方式来响
应政府的这一宏伟规划和承诺。
2006年,RDPAC在IFPMA的支持
与指导下修改了行业的推广行为准
则; 而2012年,我们在更加深入
地了解患者和其他利益相关方需求
的基础上,即将进一步强化行业的
推广行为准则。研发制药行业的贡
献有目共睹,但我们也意识到,只
有每天认真地对待每一次与我们所
服务的医疗卫生专业人员和患者的
互动,我们才能最终获得真正的信
任。2012版行为准则 在前一版的
基础上做了重大改进,以十二个条
Chairman’s Message
The Chinese Government’s vision
and commitment to significantly improve
the wellness of the Chinese
people are well articulated in the
new healthcare reform policy and the
recently issued National 12th 5-Year
Plan. A renewed focus on prevention,
access and insurance coverage
will fundamentally impact the positive
rate of change in the healthcare
environment.
Concurrently, it is imperative that
all stakeholders, including Industry
itself, reinforce the Government’s
commitment by adhering to the highest
standards of professional and
ethical conduct. RDPAC with the
support and guidance from IFPMA
has established its Code of Conduct
in 2006 and now has further
strengthened it in its 2012 update
after closely listening to patients and
our stakeholders. Our Industry has
been highly recognized, yet we realize
that trust is something we must
earn everyday in every interaction
with the entire healthcare community
and the patients we serve. The
2012 RDPAC Code of Conduct is a
significant step forward that clarifies
what is acceptable and what is not,
1
研
制
开
发
制
药
企
业
协
会